KB Financial Partners’s Mustang Bio MBIO Stock Holding History

KB Financial Partners’s Portfolio MBIO Stock Details MBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1	Closed	-$1K	–	645
2021 Q4	$1K	Buy	+1	New	+$1.61K	﹤0.01%	640

Other funds holding MBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

KB Financial Partners's MBIO Position: Q1 2022 in Review

KB Financial Partners sold out of Mustang Bio (MBIO) in Q1 2022, closing a stake of 1 share — an estimated $1K sold.

KB Financial Partners first reported a position in MBIO in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 81 funds tracked by Wall St. Rank hold MBIO as of Q1 2022.

KB Financial Partners reported no remaining Mustang Bio position as of Q1 2022 after selling out during the quarter.
KB Financial Partners sold 1 Mustang Bio share in Q1 2022, an estimated $1K.
KB Financial Partners first reported a position in Mustang Bio in Q4 2021 and held it in 1 quarter.
KB Financial Partners's Mustang Bio position peaked at $1K in Q4 2021.
81 funds tracked by Wall St. Rank held Mustang Bio as of Q1 2022.

Based on KB Financial Partners's 13F filing for Q1 2022, filed 17 May 2022.